hpv e6 e7 dna vaccine gx 188e

Drug Overview

The hpv e6 e7 dna vaccine gx 188e (also known as tirvalimogene teraplasmid) is an investigational, therapeutic DNA vaccine designed to treat cancers and precancerous lesions caused by high-risk Human Papillomavirus (HPV) types 16 and 18. Unlike prophylactic vaccines (like Gardasil) that prevent infection, GX-188E is intended to eliminate existing HPV-infected cells and tumors.

Developed by Genexine, the vaccine consists of a DNA plasmid encoding a fusion protein of the HPV E6 and E7 oncoproteins combined with the immune-enhancer Fms-like tyrosine kinase-3 ligand (FLT3L). This combination is designed to “prime” the immune system’s dendritic cells to recognize and destroy malignant cells expressing these specific viral proteins.

• Generic Name: Tirvalimogene teraplasmid (GX-188E).
• Drug Class: Therapeutic DNA Vaccine / Active Immunotherapy.
• Targets: HPV-16 and HPV-18 E6/E7 oncoproteins.
• Route of Administration: Intramuscular (IM) injection via electroporation (a technique using small electrical pulses to help cells absorb the DNA).
• FDA Approval Status: Investigational. As of March 2026, GX-188E is not FDA-approved. It has completed Phase II clinical trials for cervical cancer and cervical intraepithelial neoplasia (CIN) and is being evaluated in combination with checkpoint inhibitors.
  
  Get information on the hpv e6 e7 dna vaccine gx 188e. Trust our expert medical team for advanced clinical care tailored to your precise needs.

What Is It and How Does It Work? (Mechanism of Action)

GX-188E operates as an “instruction manual” for the immune system, teaching it to hunt cells that have been transformed by HPV.

1. Delivery via Electroporation

The vaccine is injected into the muscle, typically the deltoid. Immediately following the injection, a proprietary electroporation device (such as the Ichor TDS-IM) is used. The device delivers millisecond-long electrical pulses that create temporary pores in the cell membranes, allowing the DNA plasmid to enter the cells much more efficiently than a standard injection.

2. Molecular Level Mechanisms

1. Antigen Expression: Once inside the patient’s cells, the DNA plasmid utilizes the cell’s machinery to produce the HPV E6/E7 fusion protein and the FLT3L ligand.
2. Dendritic Cell Activation: The FLT3L protein acts as a specialized beacon, attracting and activating Dendritic Cells (the immune system’s “generals”).
3. T-cell Priming: These Dendritic Cells process the E6 and E7 antigens and present them to CD8+ Cytotoxic T-lymphocytes (Killer T-cells).
4. Targeted Destruction: These primed T-cells circulate through the body. When they encounter a cervical cancer cell or an HPV-infected cell, they recognize the E6/E7 proteins on its surface and release toxic enzymes (perforins and granzymes) to lyse (burst) the cancer cell.
5. Restoring Tumor Suppressors: By targeting E6 and E7, the vaccine addresses the viral “oncoproteins” that normally degrade p53 and pRb (the body’s natural tumor suppressors).

FDA-Approved Clinical Indications

There are currently no FDA-approved therapeutic indications for GX-188E.

Research and clinical trials are focused on:

• Advanced/Recurrent Cervical Cancer: Specifically evaluated in combination with the checkpoint inhibitor Pembrolizumab (Keytruda).
• Cervical Intraepithelial Neoplasia Grade 3 (CIN 3): Investigated as a non-surgical alternative to treat high-grade precancerous lesions.
• Head and Neck Squamous Cell Carcinoma (HNSCC): Studied for HPV-positive tumors of the throat and mouth.

Dosage and Administration Protocols

As an investigational agent, dosing is standardized within clinical trials to ensure a robust T-cell response.

Clinical Efficacy and Research Results

Results published between 2024 and 2026 highlight the vaccine’s ability to “sensitize” tumors to immunotherapy.

• Objective Response Rate (ORR): In a Phase II trial (NCT03444376) for advanced cervical cancer, the combination of GX-188E and Pembrolizumab showed a confirmed ORR of 35%. Notably, five patients (8.3%) achieved a Complete Response (CR).
• Efficacy in PD-L1 Negative Patients: Unlike many immunotherapies that only work if a tumor is PD-L1 positive, the GX-188E combination showed activity even in PD-L1 negative tumors (ORR of 29.2%).
• CIN 3 Regression: In trials for precancerous lesions, approximately 67% of patients showed complete histopathologic regression to a healthy state (≤CIN 1) within 36 weeks of treatment.
• Viral Clearance: Over 70% of patients who showed clinical improvement also successfully cleared the HPV virus from the treated area.

Safety Profile and Side Effects

GX-188E is generally well-tolerated, with most side effects related to the physical administration of the vaccine.

Common Side Effects:

• Injection Site Reactions (30%+): Pain, bruising, and discomfort at the site of electroporation. This is usually transient and resolves within a few days.
• Flu-like Symptoms: Mild fever, chills, and fatigue following the injection.
• Syncope (Fainting): Occasionally reported during or immediately after the electroporation procedure.

Serious Risks:

• Grade 3/4 Events: While rare (reported in ~6% of patients), serious events such as elevated liver enzymes (ALT/AST) or pericardial effusion have been noted, though these are often attributed to the combination with checkpoint inhibitors rather than the vaccine alone.
• Electroporation Sensation: The electrical pulses can cause temporary muscle twitching or sharp pain at the moment of delivery.

Research Areas

In Stem Cell and Regenerative Medicine, GX-188E is being used to study “Immune Microenvironment Reprogramming.” Researchers are investigating whether the vaccine can clear HPV-infected basal stem cells in the cervix. By eliminating the viral reservoir in these long-lived stem cells, GX-188E could prevent the “seeding” of future tumors, essentially allowing the healthy cervical tissue to regenerate without the risk of viral-induced mutations.

Patient Management and Practical Recommendations

Pre-treatment Tests:

• HPV Typing: Confirmation of HPV-16 or HPV-18 positivity is mandatory.
• Baseline Biopsy: To confirm the grade of CIN or the stage of cancer.
• PD-L1 Expression: Though the vaccine works in negative patients, knowing PD-L1 status helps doctors predict response speed.

Precautions:

• Device Safety: Electroporation may not be suitable for patients with certain implanted metal devices or pacemakers near the injection site.
• Steroid Use: High-dose systemic steroids may reduce the effectiveness of the T-cell priming.

“Do’s and Don’ts” List:

• DO expect a “pulsing” sensation during the injection; it is short-lived but unique compared to standard vaccines.
• DO follow the multi-dose schedule strictly; the “priming” and “boosting” of T-cells requires several encounters with the vaccine.
• DON’T apply topical anesthetics unless directed by the study team, as some can interfere with cell conductivity.
• DON’T ignore a high fever or sudden shortness of breath during the weeks following an injection.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. GX-188E is an investigational agent and is not currently approved by the US FDA for any indication. It is available only through participation in approved clinical trials. Always consult with a qualified oncologist or gynecologist regarding your diagnosis and eligibility for research.